MOTS-c

MOTS-c (also known as Mitochondrial ORF of 12S rRNA Type-c) is a prominently researched experimental compound classified strictly within the Mitochondrial Peptide framework. Operating primarily through advanced pharmacological pathways, it functions by regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline. with a documented biological half-life of roughly 4 hours, in preclinical investigative trials and independent academic studies, researchers utilizing MOTS-c have documented significant, quantifiable biological outcomes, primarily focusing on energy, metabolism, fat loss, longevity. Typical research protocols investigate administering 2000 to 2000mcg via subq pathways 5x/week. However, it is critically important to understand that while MOTS-c demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.